2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.
Edward B. Garon, MD, associate professor of medicine, David Geffen School of Medicine, University of California, Los Angeles, discusses the expanding treatment landscape in lung cancer.
In recent years, several immune checkpoint inhibitors have been approved in the lung cancer space, including the combination of ipilimumab (Yervoy) and nivolumab (Opdivo), says Garon.
Moreover, several targeted therapies, such as RET and MET exon 14 skipping TKIs, have further expanded the armamentarium, Garon concludes.